Details for Patent: 10,092,525

Which drugs does patent 10,092,525 protect, and when does it expire?

Patent 10,092,525 protects EPIDIOLEX and is included in one NDA.

This patent has thirty-two patent family members in nineteen countries.

Summary for Patent: 10,092,525

Title:	Use of cannabinoids in the treatment of epilepsy
Abstract:	The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s):	Guy; Geoffrey (London, GB), Wright; Stephen (London, GB), Mead; Alice (Cambridge, GB), Devinsky; Orrin (New York, NY)
Assignee:	GW Pharma Limited (Vision Park, Histon, Cambridge, GB)
Application Number:	15/449,402
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,092,525
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,092,525

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes						USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME

International Family Members for US Patent 10,092,525

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015332212
Australia	2021204353
Australia	2023258400
Brazil	112017007777